Belimumab After Rituximab in Resistant Primary Juvenile SS
Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome.
Does sequential use of rituximab and belimumab reduce the activity of SS in resistant patients
Researchers will compare the disease activity before and after the treatment of sequential use of rituximab and belimumab to see if the therapy works to treat SS.
Participants will:
Recieve Rituximab each week for 2-4 times until B%\<0.5% or B#\<20×10\^6/L Recieve Belimumab 4 weeks after the last use of Rituximab, and then every 4 weeks until week 28
Phase:
PHASE4
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Central South University Children's Hospital of Chongqing Medical University Children's Hospital of Fudan University Children's Hospital of Nanjing Medical University Children's Hospital of The Capital Institute of Pediatrics Shanghai Children's Hospital Shengjing Hospital Shenzhen Children's Hospital The Affiliated Hospital of Qingdao University The First Hospital of Jilin University Tianjin Children's Hospital